Regulatory Overhang Lifted: Piramal Shares Jump After US FDA Seals Sellersville Facility Inspection

Regulatory Overhang Lifted: Piramal Shares Jump After US FDA Seals Sellersville Facility Inspection​

Shares of Piramal Pharma surged in Thursday's trade after the company announced that the US Food and Drug Administration (US FDA) has successfully concluded the inspection of its manufacturing facility in Sellersville, Pennsylvania. The regulatory milestone provided a significant boost to investor sentiment following months of uncertainty regarding the site's status.

The stock climbed as high as 3.3% reaching Rs 173.59 on the BSE following the positive development. In an exchange filing, Piramal Pharma confirmed that the US FDA has issued an Establishment Inspection Report (EIR) for the facility. The company stated that this issuance marks the successful closure of the inspection process initiated earlier.

Impact of US FDA Clearance on Operational Continuity​

A successful closure of a US FDA inspection is typically viewed very positively by investors, as it eliminates a major regulatory overhang associated with the manufacturing unit. This clearance directly supports and validates operational continuity at the Sellersville site. The EIR issuance signifies that the inspection procedure has been formally concluded by the global regulator.

Analyst Outlook: Industry Faces Muted Earnings and Domestic Opportunity​

Despite the positive news for Piramal, broader industry forecasts from PL Capital suggest a challenging near-term period for pharmaceutical players. The brokerage anticipates muted earnings across its coverage universe in the upcoming June quarter. They project an overall EBITDA growth of 1% year-on-year for companies under review.

This tempered outlook is primarily attributed to the high base currently seen within the US business segment, which continues to act as a primary drag on overall performance. However, PL Capital notes significant domestic opportunities that are expected to counterbalance these international pressures.

Domestic Tailwinds and Strategic Growth Drivers​

The brokerage anticipates robust growth in the domestic formulations business across the sector. This growth is expected to be driven by strong traction within chronic therapies alongside a recovery observed in acute demand segments. Furthermore, the launch of generic semaglutide following the March 2026 patent expiry is cited as a critical catalyst for supporting sustained domestic expansion.

The entire pharmaceutical industry remains positive in outlook due to stable pricing dynamics and resilient domestic demand. The depreciation of the INR provides beneficial currency tailwinds, complemented by relatively benign input costs throughout the sector. Companies successfully targeting limited-competition launches and complex generics are expected to particularly outperform globally.

Segment Performance Assessment and Margin Pressure​

PL Capital maintains a favorable view on IPCA Laboratories and Ajanta Pharma, expecting them to post healthy earnings performance in the near term. Similarly, they expect favorable EBITDA growth for Lupin, Torrent Pharmaceuticals, and Divi's Laboratories.

However, the brokerage highlighted persistent margin pressure for Dr Reddy's Laboratories, Cipla, Zydus Lifesciences, and Anthem Biosciences. This expected compression is driven by their high US segment exposure coupled with an unfavorable product mix in that market. On the US business front, while revenue across the coverage universe is anticipated to decline year-on-year in constant currency due to gRevlimid sales, the underlying operational health of these companies is assessed as stable and steady.